JPMorgan Chase & Co. Raises Stock Position in Capricor Therapeutics Inc (NASDAQ:CAPR)

JPMorgan Chase & Co. boosted its position in shares of Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) by 419.5% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 56,199 shares of the biotechnology company's stock after purchasing an additional 45,381 shares during the quarter. JPMorgan Chase & Co. owned approximately 0.12% of Capricor Therapeutics worth $855,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. State Street Corp boosted its position in shares of Capricor Therapeutics by 27.8% in the 3rd quarter. State Street Corp now owns 512,313 shares of the biotechnology company's stock worth $7,792,000 after buying an additional 111,291 shares in the last quarter. Point72 Asset Management L.P. purchased a new position in shares of Capricor Therapeutics during the 3rd quarter worth approximately $3,806,000. PFM Health Sciences LP acquired a new position in shares of Capricor Therapeutics during the 3rd quarter worth approximately $2,324,000. Renaissance Technologies LLC lifted its stake in Capricor Therapeutics by 158.7% in the 2nd quarter. Renaissance Technologies LLC now owns 137,500 shares of the biotechnology company's stock valued at $656,000 after buying an additional 84,350 shares in the last quarter. Finally, Marshall Wace LLP acquired a new stake in Capricor Therapeutics during the 2nd quarter valued at $426,000. Institutional investors and hedge funds own 21.68% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on CAPR shares. Cantor Fitzgerald boosted their price target on Capricor Therapeutics from $25.00 to $30.00 and gave the stock an "overweight" rating in a report on Thursday, November 14th. Piper Sandler started coverage on shares of Capricor Therapeutics in a research note on Monday, October 21st. They issued an "overweight" rating and a $35.00 target price for the company. Finally, HC Wainwright reaffirmed a "buy" rating and set a $77.00 price target on shares of Capricor Therapeutics in a research note on Thursday, January 2nd. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating to the company. According to data from MarketBeat.com, Capricor Therapeutics currently has an average rating of "Moderate Buy" and a consensus target price of $34.50.

Capricor Therapeutics Stock Performance

NASDAQ CAPR traded up $0.27 during trading hours on Friday, hitting $14.80. 465,540 shares of the company's stock were exchanged, compared to its average volume of 732,321. The firm has a market capitalization of $672.96 million, a P/E ratio of -13.96 and a beta of 4.08. The business's 50 day moving average is $15.06 and its 200-day moving average is $11.94. Capricor Therapeutics Inc has a 12-month low of $3.52 and a 12-month high of $23.40.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.